Zimmer Biomet (ZBH) Raised to “Buy” at Deutsche Bank

Zimmer Biomet (NYSE:ZBH) was upgraded by equities research analysts at Deutsche Bank from a “hold” rating to a “buy” rating in a research note issued on Tuesday, November 14th. The brokerage currently has a $128.00 target price on the medical equipment provider’s stock. Deutsche Bank’s price target suggests a potential upside of 11.72% from the company’s current price.

ZBH has been the topic of several other research reports. Jefferies Group restated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. Stifel Nicolaus reiterated a “hold” rating and set a $120.00 target price on shares of Zimmer Biomet in a research report on Friday, November 3rd. Gabelli started coverage on Zimmer Biomet in a report on Thursday, August 24th. They issued a “buy” rating and a $142.00 price objective on the stock. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet in a research note on Monday, October 2nd. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $133.71.

Zimmer Biomet (ZBH) traded down $2.53 during mid-day trading on Tuesday, hitting $114.57. 1,490,000 shares of the company’s stock traded hands, compared to its average volume of 1,398,749. Zimmer Biomet has a 1-year low of $99.59 and a 1-year high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. The stock has a market capitalization of $23,197.33, a price-to-earnings ratio of 14.20, a price-to-earnings-growth ratio of 1.78 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same quarter last year, the company earned $1.79 EPS. The business’s revenue was down .8% compared to the same quarter last year. sell-side analysts expect that Zimmer Biomet will post 8.03 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ingalls & Snyder LLC boosted its position in Zimmer Biomet by 2.6% during the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after purchasing an additional 507 shares in the last quarter. Koch Industries Inc. boosted its position in Zimmer Biomet by 49,697.3% during the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares in the last quarter. Jensen Investment Management Inc. boosted its position in Zimmer Biomet by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock worth $751,000 after purchasing an additional 1,140 shares in the last quarter. Andra AP fonden boosted its position in Zimmer Biomet by 15.8% during the second quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock worth $2,735,000 after purchasing an additional 2,900 shares in the last quarter. Finally, Commerce Bank lifted its position in shares of Zimmer Biomet by 1.5% in the second quarter. Commerce Bank now owns 218,171 shares of the medical equipment provider’s stock valued at $28,013,000 after acquiring an additional 3,142 shares in the last quarter. 86.21% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was originally published by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://baseballnewssource.com/markets/zimmer-biomet-holdings-inc-zbh-upgraded-by-deutsche-bank-ag-to-buy/1782740.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.